Patents by Inventor D. Scott Wilbur

D. Scott Wilbur has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20230131121
    Abstract: Disclosed are general and “substantially pure” branched discrete polyethylene glycol constructs useful in attaching to a variety of biologically active groups, for example, preferential locators, as well as biologics like enzymes, for use in diagnostics, e.g. imaging, therapeutics, theranostics, and moieties specific for other applications. In its simplest intermediate state, a branched branched discrete polyethylene glycol construct is terminated at one end by a chemically reactive moiety, “A”, a group that is reactive with a biologic material that creates “A”, which is a biologically reactive group, connected through to a branched core (BC) which has attached at least two dPEG-containing chains, indicated by the solid line, , having terminal groups, which can be charged, non-reactive or reactable moieties and containing between about 2 and 64 dPEG residues.
    Type: Application
    Filed: May 27, 2022
    Publication date: April 27, 2023
    Inventors: Paul D. DAVIS, D. Scott WILBUR
  • Patent number: 11505525
    Abstract: Disclosed are general and “substantially pure” branched discrete polyethylene glycol constructs useful in attaching to a variety of biologically active groups, for example, preferential locators, as well as biologics like enzymes, for use in diagnostics, e.g. imaging, therapeutics, theranostics, and moieties specific for other applications. In its simplest intermediate state, a branched discrete polyethylene glycol construct is terminated at one end by a chemically reactive moiety, “A”, a group that is reactive with a biologic material that creates “A”, which is a biologically reactive group, connected through to a branched core (BC) which has attached at least two dPEG-containing chains, indicated by the solid line, , having terminal groups, which can be charged, non-reactive or reactable moieties and containing between about 2 and 64 dPEG residues.
    Type: Grant
    Filed: June 23, 2017
    Date of Patent: November 22, 2022
    Assignees: Quanta BioDesign, Ltd., University of Washington
    Inventors: Paul D. Davis, D. Scott Wilbur
  • Publication number: 20220354974
    Abstract: Reagents and methods for labeling biomolecules with astatine isotopes in higher oxidation states. The reagents and methods allow for efficient labeling of biomolecules, such as antibodies, without the formation of high molecular weight by products that arise due to 211At-promoted dimerization and higher aggregation of the conjugated biomolecules, and diminish cellular retention of astatine caused by cellular oxidization of the bonded astatine atom in vivo.
    Type: Application
    Filed: April 26, 2022
    Publication date: November 10, 2022
    Applicant: University of Washington
    Inventors: D. Scott Wilbur, Ming-Kuan Chyan, Donald K. Hamlin
  • Publication number: 20200317612
    Abstract: Disclosed are general and “substantially pure” branched discrete polyethylene glycol constructs useful in attaching to a variety of biologically active groups, for example, preferential locators, as well as biologics like enzymes, for use in diagnostics, e.g. imaging, therapeutics, theranostics, and moieties specific for other applications. In its simplest intermediate state, a branched branched discrete polyethylene glycol construct is terminated at one end by a chemically reactive moiety, “A”, a group that is reactive with a biologic material that creates “A”, which is a biologically reactive group, connected through to a branched core (BC) which has attached at least two dPEG-containing chains, indicated by the solid line, , having terminal groups, which can be charged, non-reactive or reactable moieties and containing between about 2 and 64 dPEG residues.
    Type: Application
    Filed: October 10, 2019
    Publication date: October 8, 2020
    Applicants: Quanta BioDesign, Ltd, University of Washington
    Inventors: Paul D. Davis, D. Scott Wilbur
  • Publication number: 20170313656
    Abstract: Disclosed are general and “substantially pure” branched discrete polyethylene glycol constructs useful in attaching to a variety of biologically active groups, for example, preferential locators, as well as biologics like enzymes, for use in diagnostics, e.g. imaging, therapeutics, theranostics, and moieties specific for other applications. In its simplest intermediate state, a branched discrete polyethylene glycol construct is terminated at one end by a chemically reactive moiety, “A”, a group that is reactive with a biologic material that creates “A”, which is a biologically reactive group, connected through to a branched core (BC) which has attached at least two dPEG-containing chains, indicated by the solid line, , having terminal groups, which can be charged, non-reactive or reactable moieties and containing between about 2 and 64 dPEG residues.
    Type: Application
    Filed: June 23, 2017
    Publication date: November 2, 2017
    Inventors: Paul D. Davis, D. Scott Wilbur
  • Publication number: 20160053345
    Abstract: This disclosure relates to methods for purifying and isolating astatine-211 from bismuth metal. Also disclosed are automated methods for purifying and isolating astatine-211 from bismuth metal.
    Type: Application
    Filed: August 21, 2015
    Publication date: February 25, 2016
    Inventors: D. Scott Wilbur, Ming-Kuan Chyan, Donald K. Hamlin, Katherine Gagnon, Shigeki Watanabe
  • Patent number: 8951499
    Abstract: A reagent for conjugation to a biomolecule, wherein the reagent is a single molecule with at least three functional parts and has schematic structure (I): a) wherein a trifunctional cross-linking moiety is coupled to b) an affinity ligand via a linker 1, said affinity ligand being capable of binding with another molecule having affinity for said ligand, to c) an effector agent, optionally via a linker 2, said effector agent exerting its effect on cells, tissues and/or humorous molecules in vivo or ex vivo, and to d) a biomolecule reactive moiety, optionally via a linker 3, said moiety being capable of forming a bond between the reagent and the biomolecule.
    Type: Grant
    Filed: September 6, 2006
    Date of Patent: February 10, 2015
    Assignees: University of Washington, Glycorex Transplantation AB
    Inventors: D. Scott Wilbur, Bengt E. B. Sandberg
  • Publication number: 20130052130
    Abstract: Disclosed are general and “substantially pure” branched discrete polyethylene glycol constructs useful in attaching to a variety of biologically active groups, for example, preferential locators, as well as biologics like enzymes, for use in diagnostics, e.g. imaging, therapeutics, theranostics, and moieties specific for other applications. In its simplest intermediate state, a branched discrete polyethylene glycol construct is terminated at one end by a chemically reactive moiety, “A”, a group that is reactive with a biologic material that creates “A”, which is a biologically reactive group, connected through to a branched core (BC) which has attached at least two dPEG-containing chains, indicated by the solid line, , having terminal groups, which can be charged, non-reactive or reactable moieties and containing between about 2 and 64 dPEG residues.
    Type: Application
    Filed: August 30, 2012
    Publication date: February 28, 2013
    Applicants: UNIVERSITY OF WASHINGTON, QUANTA BIODESIGN, LTD.
    Inventors: Paul D. Davis, D. Scott Wilbur
  • Patent number: 7141676
    Abstract: Water-soluble discrete multi-biotin-containing compounds with at least three (3) biotin moieties are disclosed. The water-soluble biotin-containing compounds may additionally comprise one or more moieties that confer resistance to cleavage by biotinidase or that is cleavable in vitro or in vivo. The discrete multi-biotin-containing compounds may include a reactive moiety that provides a site for reaction with yet another moiety, such as a targeting, diagnostic or therapeutic functional moiety. Biotinylation reagents comprising water-soluble linker moieties are also disclosed and may additionally comprise a biotinidase protective group. Methods for amplifying the number of sites for binding biotin-binding proteins at a selected target using multi-biotin compounds also are disclosed.
    Type: Grant
    Filed: September 30, 2002
    Date of Patent: November 28, 2006
    Assignee: University of Washington
    Inventors: D. Scott Wilbur, Pradip M. Pathare, Donald K. Hamlin, Feng Wan
  • Patent number: 6492560
    Abstract: The present invention provides discrete-length polyethylene glycol and polyethylene glycol containing compounds and methods for their preparation.
    Type: Grant
    Filed: September 24, 2001
    Date of Patent: December 10, 2002
    Assignee: The University of Washington
    Inventors: D. Scott Wilbur, Pradip M. Pathare
  • Publication number: 20020159994
    Abstract: A method for the conditioning of an extracorporeal device is described, as well as a method for extracorporeal extraction of toxic material from mammalian body fluids in connection with diagnosis or treatment of a mammalian condition or disease, in which methods reagents having the ability to extract toxic material from mammalian body fluids are involved, and an extracorporeal device comprising said reagent.
    Type: Application
    Filed: June 15, 2001
    Publication date: October 31, 2002
    Inventors: Bengt E.B. Sandberg, D. Scott Wilbur, Rune Nilsson
  • Publication number: 20020091288
    Abstract: The present invention provides discrete-length polyethylene glycol and polyethylene glycol containing compounds and methods for their preparation.
    Type: Application
    Filed: September 24, 2001
    Publication date: July 11, 2002
    Applicant: The University of Washington
    Inventors: D. Scott Wilbur, Pradip M. Pathare
  • Patent number: 6294697
    Abstract: The present invention provides discrete-length polyethylene glycol and polyethylene glycol containing compounds and methods for their preparation.
    Type: Grant
    Filed: April 17, 1998
    Date of Patent: September 25, 2001
    Assignee: The University of Washington
    Inventors: D. Scott Wilbur, Pradip M. Pathare
  • Publication number: 20010023288
    Abstract: A reagent for conjugation to a biomolecule, wherein the reagent is a single molecule with at least three functional parts and has schematic structure (I): wherein a trifunctional cross-linking moiety is coupled to b) an affinity ligand via a linker 1, said affinity ligand being capable of binding with another molecule having affinity for said ligand, to c) an effector agent, optionally via a linker 2, said effector agent exerting its effect on cells, tissues and/or humorous molecules in vivo or ex vivo, and to d) a biomolecule reactive moiety, optionally via a linker 3, said moiety being capable of forming a bond between the reagent and the biomolecule.
    Type: Application
    Filed: December 29, 2000
    Publication date: September 20, 2001
    Inventors: D. Scott Wilbur, Bengt E.B. Sandberg
  • Patent number: 6083926
    Abstract: Vitamin B.sub.12 receptor modulating agents capable of modulating cell surface receptors by affecting the cell surface receptor trafficking pathway are disclosed. The vitamin B.sub.12 receptor modulating agents are comprised of a covalently bound rerouting moiety and targeting moiety linked by a water-solublizing linker.
    Type: Grant
    Filed: November 23, 1998
    Date of Patent: July 4, 2000
    Assignees: The University of Washington, Receptagen Corporation
    Inventors: A. Charles Morgan, Jr., D. Scott Wilbur, Pradip M. Pathare
  • Patent number: 5869465
    Abstract: Receptor modulating agents capable of modulating cell surface receptors by affecting the cell surface receptor trafficking pathway are utilized for the treatment and diagnosis of a variety of disorders in warm-blooded animals, including neoplastic disorders. The receptor modulating agents are comprised of a covalently bound rerouting moiety and targeting moiety.
    Type: Grant
    Filed: March 16, 1995
    Date of Patent: February 9, 1999
    Assignees: Receptagen Corporation, University of Washington
    Inventors: A. Charles Morgan, Jr., D. Scott Wilbur
  • Patent number: 5840880
    Abstract: Receptor modulating agents capable of modulating cell surface receptors by affecting the cell surface receptor trafficking pathway. The receptor modulating agents are comprised of a covalently bound rerouting moiety and targeting moiety.
    Type: Grant
    Filed: March 16, 1995
    Date of Patent: November 24, 1998
    Assignees: Receptagen Corporation, University of Washington
    Inventors: A. Charles Morgan, Jr., D. Scott Wilbur
  • Patent number: 5840712
    Abstract: Vitamin B.sub.12 receptor modulating agents capable of modulating cell surface receptors by affecting the cell surface receptor trafficking pathway are disclosed. The vitamin B.sub.12 receptor modulating agents are comprised of a covalently bound rerouting moiety and targeting moiety linked by a water-solublizing linker.
    Type: Grant
    Filed: October 19, 1995
    Date of Patent: November 24, 1998
    Assignees: Receptagen Corporation, University of WA
    Inventors: A. Charles Morgan, Jr., D. Scott Wilbur, Pradip M. Pathare
  • Patent number: 5739287
    Abstract: A biotinylated cobalamin, formed from a vitamin B.sub.12 molecule coupled to a biotin molecule, is disclosed. In a preferred embodiment, the vitamin B.sub.12 molecule is cyanocobalamin. The biotin molecule can also be coupled to a rerouting moiety, optionally through a biotin binding protein such as avidin or streptavidin. The biotinylated cobalamin binds to a cell surface receptor, is invaginated, and once internalized affects the receptor trafficking pathway.
    Type: Grant
    Filed: March 16, 1995
    Date of Patent: April 14, 1998
    Assignees: University of Washington, Receptagen Corp.
    Inventors: D. Scott Wilbur, Pradip M. Pathare, A. Charles Morgan, Jr.
  • Patent number: 5679322
    Abstract: Highly iodinated borane and carborane cage molecules, having from 60% to 90% w/w iodine, are disclosed as new and useful X-ray contrast media when combined with a pharmaceutically acceptable carrier. The inclusion of appropriate functional group substituents, such as hydrophilic moieties, increases solubility and lowers toxicity.
    Type: Grant
    Filed: February 5, 1996
    Date of Patent: October 21, 1997
    Assignee: University of Washington
    Inventor: D. Scott Wilbur